This document describes a method for purifying human erythropoietin (EPO) from formulated drugs using reversed-phase chromatography. This method allows EPO to be purified to homogeneity for further analysis by peptide mapping, mass spectrometry and protein sequencing.
This document describes a single-step protein chemical analysis procedure for purifying human Erythropoietin (EPO) from fully formulated drug products. The method utilizes C-18 reversed-phase chromatography to separate EPO from excess non-active proteins like human serum albumin and other components.
The procedure is designed to purify Erythropoietin (EPO) from fully formulated drugs to homogeneity for further analysis.
The method uses a column with dimensions of 4.6 x 250 mm.